跳至主要内容

Analytical Method Development and Validation for Pharmaceutical

 

Process Analytical Science

Our process analytical sciences group provides support for research, development and commercial production.

At Medicilon, the importance of analytical support in pharmaceutical development and manufacturing is well understood.  We provide our clients with analytical method development and all other services required to support their regulatory needs.

Services Offered

  • Analytical Method Development, Qualification and Validation For
    • Assay
    • Related Compounds
    • Water Content
    • Chiral Analysis
    • Residual Solvents
    • Trace Metals Analysis
  • IPC and Release Testing
  • Impurity Isolation and Structure Elucidation
  • Reference Standard Qualification
  • Stability Studies
  • PGI Method Development, Validation and Testing
  • Specification and Other Regulatory Filing Documentation Preparation

We have the following key instrumentation to support our analytical activities

  • Chromatography: UPLC, HPLC, LC-MS, GC, GC-HS
  • Solid State Characterization: DSC, TGA, XRPD, PSD, Polarized Light Microscopy
  • Elemental Analysis: ICP-OES
  • Identification: NMR, FT-IR
  • General Testing: KF, UV-Vis, Polarimeter

Analytic method development, validation and transfer are key elements of any pharmaceutical development program. This technical brief will focus on development and validation activities as applied to drug products.  Often considered routine, too little attention is paid to them with regards for their potential to contribute to overall developmental time and cost efficiency.



Methods are developed and validated to analyze in-process, finished product and stability samples, as well as swabs to verify the cleanliness of manufacturing equipment.

Typically, methods for in-process, uniformity of dosage units and dissolution sample analysis are developed and validated using UV, HPLC, UPLC, or GC procedures.

Methods used to perform chemical assay, identification, related substances/impurities or chiral purity testing on API and finished drug product are typically developed and validated using HPLC, UPLC or GC.

Methods developed for stability sample analysis are validated to ensure they are stability indicating.

All validations are performed according to FDA-ICH guidelines, client-approved protocols and standard operating procedures.

Method Validation

By working with Medicilon, you gain an experienced partner with a good working knowledge of method validation requirements suitable for different phases of development. To ensure methods meet regulatory requirements, we follow relevant ICH guidelines such as ICH Q2(R1) or compendia guidance in combination with client-specific protocols.

Analytical Techniques and Capabilities Include:

UV/VIS Spectroscopy
Fluorescence Spectroscopy
ELISA
SDS-PAGE
Iso-electric Focusing
Capillary Gel Electrophoresis
UPLC
HPLC
Atomic Adsorption
FTIR
Peptide Mapping
Carbohydrate Analysis
Cell Based Assays

HPLC Methods: HPLC methods with variety of high resolution analytical columns represent the most effective and efficient means of monitoring various degradation of protein therapeutics.

  • Size-Exclusion Chromatography
  • Ion-Exchange Chromatography
  • Reversed Phase Chromatography
  • Hydrophobic Interaction Chromatography
  • Various Detectors: UV, Fluorescence, Reflective Index, Evaporative Light Scattering, Mass Spectrometry

The wide variety of equipment, columns, eluent and operational parameters involved high performance liquid chromatography (HPLC) method which makes the development seem complex. Following steps:
step 1 - Selection of the HPLC Method and Initial System
step 2 - Selection of Initial Conditions
step 3 - Selectivity Optimization
step 4 - System Optimization
step 5 - Method Validation

Structural Analyses: Measure the secondary, tertiary, and quaternary structure of biologically active proteins

  • Circular Dichroism
  • Fourier Transformed Infrared Spectroscopy
  • Fluorescence Spectroscopy
  • Differential Scanning Calorimetry

Electrophoresis: Separation of impurities based on both charge and mass makes electrophoresis an excellent orthogonal method

  • Capillary Electrophoresis (CE)
  • Sodium Dodecyl Sulfate Electrophoresis (SDS-PAGE)
  • Protein Analyzer

Contact Us 

Email : marketing@medicilon.com.cn
Tel : +86 021 58591500

Tips : Above is part of analytical method development, analytical method development and validation for pharmaceutical. You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.

标签：

评论

发表评论

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...
发表评论
阅读全文

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

  On July 20, 2020, DAC Biotech’s new   ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed   preclinical pharmacokinetic  and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...
发表评论
阅读全文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文